🔗 Share this article

While America continues making sweeping revisions to its vaccination recommendations, a particular individual has surfaced unexpectedly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by expressing skepticism about COVID-19 vaccinations during the pandemic and has zeroed in on potential fatalities following Covid immunization in her short tenure at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Program

Health officials were set to announce major revisions to the pediatric immunization program in December, synchronizing the US with Denmark’s immunization schedule, it is understood – a substantial departure that would place the US out of step with much of the international standard with no evidence for benefit. The planned update has been postponed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to speak at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

A New Direction at the Agency

The acting appointment might represent a closer partnership between the drug and vaccine branches as Høeg and Prasad consolidate power at the agency – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for halting some pediatric vaccine recommendations in the US so as to align more similar to Denmark, a society with nationalized medicine and a population approximately the size of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccines – typically the purview of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

The appointee has no apparent experience in medication creation, oversight or management, which has been customary for former leaders of the biologics center. She has served at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have the necessary background” for running the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She has no expertise in running a major agency. She is not an expert in industry regulation.”

Previous directors of the center would “grasp legal statutes and the science of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who headed the center have had.”

The drug center has an immense workload at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the innovative therapies, but the generic program clears numerous generic medications. There is also a biosimilars division, non-prescription drug unit and more, and each of these need to be supervised,” Woodcock noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a substantial leadership component to the role, which manages over 5,000 staff members. “It is a enormous leadership role, if you do it right,” the former official added.

Agency Reaction and Disputed Policies

In response to inquiries about Høeg’s qualifications and whether this selection indicates increased cooperation among agency officials on vaccines, a press secretary said that the “concerns are based on flawed premises”.

“Her resume aligns with the responsibilities of her role,” the official said, noting the months Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a controversial one-day medication authorization process that reportedly troubled her former heads. “How are these drugs being selected for this voucher program? Who is making the choices?” Dr. Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, except for vaccines.”

Established History on Vaccines

Concerning vaccines, Høeg has a more established, if troubling, past, critics said. She published a analysis using non-validated crowd-sourced reports to assess the rate of heart inflammation after Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are riskier than they are.

Among her “desired changes” for the incoming government featured changing regulations for novel immunizations and halting “unnecessary” vaccines, she stated post-election on a audio program. At the FDA, Dr. Høeg has reportedly suggested preventing teenage boys from getting Covid vaccinations.

“She is an complete dogmatist who starts off with her conclusions and reverse-engineers to accommodate the data in a highly disingenuous, fraudulent manner,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined fellow dissenters, {like|